| SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness KS Corbett, DK Edwards, SR Leist, OM Abiona, S Boyoglu-Barnum, ... Nature 586 (7830), 567-571, 2020 | 1503 | 2020 |
| Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates KS Corbett, B Flynn, KE Foulds, JR Francica, S Boyoglu-Barnum, ... New England Journal of Medicine 383 (16), 1544-1555, 2020 | 1178 | 2020 |
| Modified mRNA vaccines protect against Zika virus infection JM Richner, S Himansu, KA Dowd, SL Butler, V Salazar, JM Fox, ... Cell 168 (6), 1114-1125. e10, 2017 | 926 | 2017 |
| Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines KJ Hassett, KE Benenato, E Jacquinet, A Lee, A Woods, O Yuzhakov, ... Molecular Therapy-Nucleic Acids 15, 1-11, 2019 | 640 | 2019 |
| Vaccine mediated protection against Zika virus-induced congenital disease JM Richner, BW Jagger, C Shan, CR Fontes, KA Dowd, B Cao, ... Cell 170 (2), 273-283. e12, 2017 | 278 | 2017 |
| A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection N Kose, JM Fox, G Sapparapu, R Bombardi, RN Tennekoon, AD De Silva, ... Science immunology 4 (35), eaaw6647, 2019 | 196 | 2019 |
| A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques P Zhang, E Narayanan, Q Liu, Y Tsybovsky, K Boswell, S Ding, Z Hu, ... Nature medicine 27 (12), 2234-2245, 2021 | 105 | 2021 |
| An mRNA vaccine protects mice against multiple tick-transmitted flavivirus infections LA VanBlargan, S Himansu, BM Foreman, GD Ebel, TC Pierson, ... Cell reports 25 (12), 3382-3392. e3, 2018 | 100 | 2018 |
| A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus A August, HZ Attarwala, S Himansu, S Kalidindi, S Lu, R Pajon, S Han, ... Nature medicine 27 (12), 2224-2233, 2021 | 82 | 2021 |
| Zika virus RNA vaccines G Ciaramella, S Himansu, EYC Huang, T Zaks US Patent 10,124,055, 2018 | 78 | 2018 |
| Combination piv3/hmpv rna vaccines G Ciaramella, S Himansu US Patent 10,064,934, 2018 | 75 | 2018 |
| Zika RNA vaccines G Ciaramella, EYC Huang, K Bahl, T Zaks, S Himansu US Patent 10,449,244, 2019 | 67 | 2019 |
| Zika virus MRNA vaccines G Ciaramella, S Himansu US Patent 10,653,767, 2020 | 59 | 2020 |
| Sexually transmitted disease vaccines G Ciaramella, S Himansu US Patent App. 15/767,600, 2018 | 50 | 2018 |
| Sexually transmitted disease vaccines G Ciaramella, S Himansu US Patent 10,493,143, 2019 | 49 | 2019 |
| Protective efficacy of nucleic acid vaccines against transmission of zika virus during pregnancy in mice BW Jagger, KA Dowd, RE Chen, P Desai, B Foreman, KE Burgomaster, ... The Journal of infectious diseases 220 (10), 1577-1588, 2019 | 49 | 2019 |
| Zoonotic disease rna vaccines G Ciaramella, S Himansu, V Presnyak, K Benenato, ES Kumarasinghe US Patent App. 16/494,988, 2020 | 44 | 2020 |
| Respiratory virus nucleic acid vaccines G Ciaramella, S Himansu US Patent 11,103,578, 2021 | 41 | 2021 |
| Chimeric fusion (F) and attachment (G) glycoprotein antigen delivery by mRNA as a candidate Nipah vaccine RJ Loomis, AT DiPiazza, S Falcone, TJ Ruckwardt, KM Morabito, ... Frontiers in Immunology 12, 772864, 2021 | 30 | 2021 |
| Human immunoglobulin repertoire analysis guides design of vaccine priming immunogens targeting HIV V2-apex broadly neutralizing antibody precursors JR Willis, ZT Berndsen, KM Ma, JM Steichen, T Schiffner, E Landais, ... Immunity 55 (11), 2149-2167. e9, 2022 | 26 | 2022 |
